The objective of this project is the commercialization of a method for the coupled amplification and sequencing (""""""""CAS"""""""") of DNA. Kits will be produced that enable the simultaneous sequencing of both strands of multiple DNA strategy invented at Yale University and data to date have shown that: a) CAS is feasible, b) potential problem areas have been defined, c) there is a need to define the robustness of CAS by sequencing additional DNA fragments, and d) CAS is likely adaptable to the simultaneous sequencing of multiple templates. Collaborative studies by BIOS and Yale will be directed at: a) finding a thermostable DNA polymerase most compatible with CAS, b) determining optimal conditions for sequencing DNA of different fragment lengths, c) demonstrating robustness by applying CAS to different templates, and d) determining and implementing conditions for multiplex CAS. Results of these studies will show that DNA sequencing can be made simple, accessible to many researchers, and preferable to the current indirect methods for determining sequence variation. Moreover, CAS will impact large scale sequencing efforts by providing a method for direct sequencing of cosmid inserts in a single electrophoretic run.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HG000524-01
Application #
3500497
Study Section
Special Emphasis Panel (SSS (B1))
Project Start
1991-09-01
Project End
1992-12-15
Budget Start
1991-09-01
Budget End
1992-12-15
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Genaissance Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511